Omeros Faces Final EU Rejection for Narsoplimab After CHMP Re-examination

Key Facts

1The CHMP issued a negative opinion on the marketing authorization application for narsoplimab following a re-examination of its original June 2026 opinion.

The Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the marketing authorization application for narsoplimab following a formal re-examination. Omeros Corporation announced, according to a statement reported by Business Wire, that the decision maintains the committee's original stance from June 2026, effectively blocking the drug's path to the European market for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy.

OMER closed at $18.79 on October 15, 2026, prior to the confirmation of the regulatory rejection. The stock traded between a low of $18.3 and a high of $19.08 during that session, as the final rejection of a key pipeline candidate in a major market presents a significant setback for the firm's biotech operations.